Isabelle Tabah-Fisch
Overview
Explore the profile of Isabelle Tabah-Fisch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
3165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prat M, Le Naour A, Coulson K, Lemee F, Leray H, Jacquemin G, et al.
J Immunother Cancer
. 2020 Jun;
8(1).
PMID: 32503947
Background: Besides the interest of an early detection of ovarian cancer, there is an urgent need for new predictive and prognostic biomarkers of tumor development and cancer treatment. In healthy...
2.
Liu J, Ray-Coquard I, Selle F, Poveda A, Cibula D, Hirte H, et al.
J Clin Oncol
. 2016 Dec;
34(36):4345-4353.
PMID: 27998236
Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) -mediated ErbB3 signaling and inducing ErbB3...
3.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al.
N Engl J Med
. 2011 Oct;
365(14):1273-83.
PMID: 21991949
Background: Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy...
4.
Press M, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, et al.
J Clin Oncol
. 2010 Dec;
29(7):859-67.
PMID: 21189395
Purpose: Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. This study was designed to...
5.
Ribeiro R, Steliarova-Foucher E, Magrath I, Lemerle J, Eden T, Forget C, et al.
Lancet Oncol
. 2008 Aug;
9(8):721-9.
PMID: 18672210
Background: Childhood-cancer survival is dismal in most low-income countries, but initiatives for treating paediatric cancer have substantially improved care in some of these countries. The My Child Matters programme was...
6.
Ejaz A, Mu W, Kang D, Roncal C, Sautin Y, Henderson G, et al.
Clin J Am Soc Nephrol
. 2007 Aug;
2(1):16-21.
PMID: 17699382
Acute renal failure (ARF), induced by either toxins or ischemia, is associated with significant morbidity. The pathogenesis of ARF is complex and is characterized by renal vasoconstriction and oxidative stress...
7.
De Gramont A, Buyse M, Abrahantes J, Burzykowski T, Quinaux E, Cervantes A, et al.
J Clin Oncol
. 2007 Aug;
25(22):3224-9.
PMID: 17664470
Purpose: In the OPTIMOX1 trial, previously untreated patients with advanced colorectal cancer were randomly assigned to two different schedules of leucovorin, fluorouracil, and oxaliplatin that were administered until progression in...
8.
Roncal C, Mu W, Croker B, Reungjui S, Ouyang X, Tabah-Fisch I, et al.
Am J Physiol Renal Physiol
. 2007 Jan;
292(1):F116-22.
PMID: 17210794
Marked hyperuricemia is known to cause acute renal failure via intrarenal crystal deposition. However, recent studies suggest mild hyperuricemia may have vasoactive and proinflammatory effects independent of crystal formation. We...
9.
Goldberg R, Tabah-Fisch I, Bleiberg H, De Gramont A, Tournigand C, Andre T, et al.
J Clin Oncol
. 2006 Sep;
24(25):4085-91.
PMID: 16943526
Purpose: Oxaliplatin, fluorouracil, and leucovorin are commonly used to treat advanced and resected colorectal cancer. This analysis compares the safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly (FOLFOX4) in...
10.
Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al.
J Clin Oncol
. 2006 Jan;
24(3):394-400.
PMID: 16421419
Purpose: In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is a standard first-line regimen. The cumulative neurotoxicity of oxaliplatin often requires therapy...